Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Subcutaneous administration suffers from: Lower bioavailability Variable absorption Different pharmacokinetics Which means the systemic exposure of DSIP via subcutaneous administration is not equivalent to what is achieved with intravenous infusion
PT-141 Research# PT-141 completed the full drug development pathway: RECONNECT trials : Two Phase 3 pivotal trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores compared to placebo, with a meaningful increase in satisfying sexual events FDA approval : Approved June 21, 2019, as Vyleesi for HSDD in premenopausal women Male sexual dysfunction : Earlier trials explored PT-141 for male erectile dysfunction, though this indication was not pursued to approval Dose limitations : FDA label restricts use to no more than 8 doses per month and recommends against use in patients with uncontrolled hypertension or cardiovascular disease Post-marketing : Ongoing pharmacovigilance with established adverse event reporting The regulatory gap between MT-2 and PT-141 is the fundamental differentiator: PT-141 has undergone the rigorous efficacy and safety evaluation required for FDA approval, while MT-2 has not
The recommended dose of glutathione for skin whitening is 250 mg/ day
These websites provide useful resources to help lower your out-of-pocket costs, even if you dont have insurance or your insurance doesnt cover the medication
